Method of inhibiting nonspecific reaction in PIVKA-II assay reagent

Patent metadata

Field	Value
Publication number	US-9952230-B2
Application number	US-201214116155-A
Country	US
Kind code	B2
Filing date	May 23, 2012
Priority date	May 23, 2011
Publication date	Apr 24, 2018
Grant date	Apr 24, 2018

Abstract

A problem to be solved by the present invention is to inhibit a nonspecific agglutination reaction in an agglutination test using a monoclonal antibody having a property of specifically biding to PIVKA-II and a monoclonal antibody having a property of specifically biding to prothrombin as well as two types of carrier particles carrying these monoclonal antibodies. The nonspecific agglutination reaction can be inhibited by adding certain divalent metal ions to a reaction solution containing the monoclonal antibody having a property of specifically biding to PIVKA-II and the monoclonal antibody having a property of specifically biding to prothrombin as well as the two types of carrier particles carrying these monoclonal antibodies.

First claim

The invention claimed is:

1. A method of measuring concentration of PIVKA-II in a biological sample comprising the steps of:
bringing first carrier particles to which a first monoclonal antibody is immobilized and second carrier particles to which a second monoclonal antibody is immobilized into contact with the biological sample in which prothrombin may exist under the presence of divalent metal ions; and
optically measuring agglutination of said first carrier particles and said second carrier particles to determine the concentration of PIVKA-II,
wherein one of the first and second monoclonal antibodies is an antibody specifically binding to PIVKA-II in the absence of calcium ion while the other is an antibody specifically binding to prothrombin,
wherein both antibodies bind to different epitopes, and
wherein the divalent metal ions are ions of one or more selected from the group consisting of Be 2+ , Mg 2+ , Ca 2+ , Sr 2+ , Ba 2+ , and Ra 2+ and are not derived from the biological sample.

2. The method according to claim 1 , wherein the divalent metal ions are ions of one or more selected from the group consisting of Mg 2+ and Ca 2+ .

3. The method according to claim 1 or 2 , wherein the first or second carrier particles are latex particles.

4. The method according to claim 1 , wherein the step of bringing into contact and the step of measuring are performed in the same reaction solution or in the same reaction vessel.

5. A reagent for measuring concentration of PIVKA-H through an agglutination reaction comprising:
first carrier particles to which a first monoclonal antibody is immobilized;
second carrier particles to which a second monoclonal antibody is immobilized; and
divalent metal ions,
wherein one of the first and second monoclonal antibodies is an antibody specifically binding to PIVKA-II in the absence of calcium ion while the other is an antibody specifically binding to prothrombin,
wherein both antibodies bind to different epitopes, and
wherein the divalent metal ions are ions of one or more selected from the group consisting of Be 2+ , Mg 2+ , Ca 2+ , Sr 2+ , Ba 2+ , and Ra 2+ .

6. The reagent according to claim 5 , wherein neither the first carrier particles nor the second carrier particles are fluorescent carrier particles.

7. A kit of parts for measuring concentration of PIVKA-II through an agglutination reaction comprising:
a first reagent containing divalent metal ions; and
a second reagent containing first carrier particles to which a first monoclonal antibody is immobilized and second carrier particles to which a second monoclonal antibody is immobilized,
wherein one of the first and second monoclonal antibodies is an antibody specifically binding to PIVKA-II in the absence of calcium ion while the other is an antibody specifically binding to prothrombin,
wherein both antibodies bind to different epitopes, and
wherein the divalent metal ions are ions of one or more selected from the group consisting of Be 2+ , Mg 2+ , Ca 2+ , Sr 2+ , Ba 2+ , and Ra 2+ .

8. The kit of parts according to claim 7 , wherein neither the first carrier particles nor the second carrier particles are fluorescent carrier particles.

9. The method according to claim 1 , wherein the biological sample is a sample in which prothrombin exists.

10. The method according to claim 1 , wherein the biological sample is blood, serum, plasma, or lymph fluid.

Assignees

• Matsumoto Takuji
• Yamamoto Mitsuaki
• Sekisui Medical Co Ltd

Inventors

• Matsumoto Takuji
• Yamamoto Mitsuaki

Classifications

• G01N33/541 Primary

  Double or second antibody {, i.e. precipitating antibody} · CPC title

• G01N33/86 Primary

  involving blood coagulating time {or factors, or their receptors} · CPC title

• G01N33/542

  with steric inhibition or signal modification, e.g. fluorescent quenching · CPC title

• G01N33/82

  involving vitamins {or their receptors} · CPC title

• G01N33/53 Primary

  Immunoassay; Biospecific binding assay; Materials therefor · CPC title